a-Melanocyte-stimulating hormone (a-MSH) is a tridecapeptide derived from proopiomelanocortin that exhibits potent anti-inflammatory properties by regulating the production of inflammatory mediators. This peptide has been well established in several inflammatory models, including inflammatory bowel disease (IBD). However, its extremely short duration in vivo limits its clinical application. To address this limitation, Bifidobacterium was used here as a carrier to deliver a-MSH. We utilized a-MSH-engineered Bifidobacterium against IBD, which is closely linked to immune and intestinal microbiota dysfunction. First, we constructed a Bifidobacterium longum secreting a-MSH (B. longum-a-MSH). We then tested the recombinant a-MSH expression and determined its bioactivity in HT-29 cells. To assess its effectiveness, B. longum-a-MSH was used against an ulcerative colitis (UC) model in rats induced by dextran sulfate sodium. The data showed that a-MSH expression in B. longum-a-MSH was effective, and its biological activity was similar to the synthesized one. This UC model experiment indicated that B. longum-a-MSH successfully colonized the intestinal gut, expressed bioactive a-MSH and had a significant anti-inflammatory effect. The results demonstrate the feasibility of preventing IBD by using B. longum-a-MSH.
INTRODUCTION
a-Melanocyte-stimulating hormone (a-MSH) is a neuropeptide derived from pro-opiomelanocortin. In the last few decades, numerous studies focusing on a-MSH have provided substantial evidence that this hormone exhibits potent protection, immunomodulation and anti-inflammatory effects. The immunomodulating and anti-inflammatory effects of a-MSH can be elicited via downregulation of pro-inflammatory cytokines and mediators such as IL-1, IL-2, IL-4, IL-6, IL-8, IL-1b, TNF-a and nitric oxide (NO), as well as upregulation of the anti-inflammatory cytokine IL-10 production (Brzoska et al., 2010) . Moreover, an animal model experiment using a-MSH has been demonstrated in various inflammatory diseases, such as irritant and allergic contact dermatitis, vasculitis, inflammatory bowel disease (IBD), allergic airway inflammation, arthritis, acute pancreatitis, and liver, ocular and brain inflammation (Brzoska et al., 2008; Carniglia et al., 2013; Moraes et al., 2014; Tennoune et al., 2014) . These diverse physiological and biological capabilities suggest that a-MSH may be a promising therapeutic drug for various inflammatory diseases as mentioned above (Brzoska et al., 2008) . Given that the half-life of full-length a-MSH is only a few minutes in vivo (Temp et al., 2013) , continuous injections are needed to maintain the therapeutic effects of the hormone. This limitation makes a-MSH unsuitable as a drug. Therefore, an efficient strategy for delivering a-MSH should be developed.
Bifidobacterium spp. are non-pathogenic bacteria that represent one of the most dominant groups of intestinal microflora in humans, and these species have a fundamental function from birth to old age (Martinez et al., 2013) . Many studies have reported that Bifidobacterium spp. confer many health-promoting properties for humans, such as immunomodulatory and gastrointestinal functions; nutrient synthesis; improvement against lactose intolerance, diarrhoea, cancer, inflammation, allergies, microbial infection; and serum cholesterol reduction (Medina et al., 2007; Quigley, 2011; Arena et al., 2014; Tsai et al., 2014) . Given these beneficial effects, some strains of Bifidobacterium have been used as probiotics, which are widely used in food science, medicine and industry.
Furthermore, Bifidobacterium has become popular in the field of medicine because it has high security, elicits prominent abilities of fermentation, resists the extreme intestinal environment and adapts to its specific local communities (Meile et al., 2008; Turroni et al., 2011) .
IBD, which includes ulcerative colitis (UC) and Crohn's disease, is an intractable disease. The exact aetiology of IBD is still unknown. A large amount of work in recent decades has made the problem less ambiguous, showing that IBD is related to certain factors like intestinal microflora and immune response (Strober et al., 2007) . It is now widely accepted that inflammatory cytokines play a crucial role in immune dysregulation and IBD development (SanchezMunoz et al., 2008) . Considering the complicated nature of IBD, the intestinal microflora must be regulated, and anti-inflammatory action is needed for therapy.
Here, we undertook the construction of a Bifidobacterium longum expressing a-MSH, and its oral delivery to combat UC in a rat model induced by dextran sulfate sodium (DSS). We used B. longum as a delivery system to make the short half-life a-MSH peptide feasible for oral administration and to combine the regulation of intestinal flora with control of inflammatory reaction for IBD treatment.
METHODS
Construction of Bifidobacterium secreting a-MSH. The bacterial strains and plasmids used in this research are listed in Table 1 . Escherichia coli DH5a was used for general cloning purposes and grown at 37 uC in Luria-Bertani broth with vigorous shaking. Bifidobacterium strains were grown in MRS (de Man, Rogosa and Sharp) medium supplemented with 0.05 % (w/v) L-cysteine at 37 uC under anaerobic conditions. The hup gene promoter and terminator were PCR amplified from B. longum HB15. The expression fragment was synthesized and consisted of an optimal ribosome-binding site (RBS), an amylase (amyB) signal sequence and the a-MSH gene, and the hup gene promoter and terminator were ligated into a shuttle vector, pDG7, to yield a 7.7 kb plasmid named pDGMSH (Fig. 1) . Plasmid DNA preparation from E. coli, restriction-enzyme digestion, ligation and E. coli transformation were performed as described by Sambrook and Russell (2001) . The plasmid was transformed into B. longum by electroporation, as described previously (Turroni et al., 2014) . The transformants were screened via an agar-containing culture medium containing ampicillin (100 mg l 21 final concentration) in anaerobic conditions. Transformed cells were cultivated in MRS agar broth containing 3 mg chloramphenicol ml 21 .
Expression and identification. Recombinant human a-MSH (rha-MSH) was separated by sodium bis(2-ethylhexyl) sulfosuccinate PAGE, a small peptides separation system, and was detected by Western blotting. The levels of rha-MSH in Bifidobacterium culture supernatants were measured quantitatively by ELISA. After 20 h, inoculation in buffered DMEM (Dulbecco's Modified Eagle Medium) containing 3 mg chloramphenicol ml 21 was performed as required under anaerobic conditions. The culture supernatants were collected and filtered through 0.22 mm membranes and 5 kDa ultrafiltration membranes (Millipore Amicon). Then the supernatants were precipitated with trichloroacetic acid (15 % w/v), and the pellets were dissolved in PBS. Sodium bis(2-ethylhexyl) sulfosuccinate PAGE was performed as described previously (Lu et al., 2007) . Anti-a-MSH antibodies (LSBio) were used for Western blot analysis according to the manufacturer's instructions. Synthesized a-MSH (GLS) was used as a standard. Secretion of rha-MSH in cell culture supernatants was detected on properly diluted samples using an a-MSH ELISA kit (IBL-America) according to the manufacturer's protocols at 0, 5, 10, 15, 20, 25 and 30 h.
Bioactivity assay. HT-29 cells were cultured in RPMI 1640 supplemented with 10 % (v/v) fetal bovine serum containing 10 mg ampicillin ml 21 at 37 uC in humidified 5 % CO 2 until the experiments were performed. Cells were seeded into 24-well plates at a density of 2|10 6 cells per well. Bifidobacterial culture supernatants were sterilized by filtration through 0.22 mm membranes and adjusted to an anticipated concentration (containing 80 pg rha-MSH ml 21 ). After removing the growth medium, the cells were incubated with bifidobacterial culture supernatants diluted 1 : 1 (v/v) with fresh medium. After 1 h of preliminary incubation, cells were exposed to 5 mg LPS (E. coli; Sigma) ml 21 . After another 4 h, cells were harvested for immunoblotting of NF-kB using an NF-kB p65 kit (Beyotime) as described previously (Fabrikant et al., 2013) . The amount of released Oral Bifidobacterium expressing a-MSH to combat UC IL-8 in the supernatants was determined using an ELISA kit (MultiSciences).
Animal assays. These experiments were performed in accordance with the Animal Care and Use Committee of Jinan University, China. A total of 48 non-pathogenic Sprague-Dawley rats (24 males and 24 females) weighing 230-250 g were obtained from the Third Military Medical University and housed in comfortable cages. The rats were randomly assigned to four groups and allowed to acclimatize to standard lighting and temperature conditions with freely available food and water. For induction of colitis, rats received 4 % DSS by drinking water for 1 week. The control group was provided with tap water only. After being administered with DSS, the DSS-only group was orally administered daily with PBS; the WT/DSS group was orally administered daily with WT B. longum HB15 (2|10 10 c.f.u. per rat per day); the B. longum-a-MSH/DSS group was orally administered daily with B. longum expressing a-MSH (2|10 10 c.f.u. per rat per day). At 1, 3, 5 and 7 days after administration, 12 rats were euthanized, and colon tissues were harvested and snap frozen, for myeloperoxidase (MPO), TNF-a, IL-6, IL-10, NO and faecal Bifidobacterium analysis.
Histological evaluation. On day 7 of Bifidobacterium administration, samples from the middle colon were selected and cleaned with physiological saline, and then fixed in 4 % buffered formaldehyde (pH 7.4). The samples were dehydrated by increasing ethanol concentrations, and embedded in paraffin, continuously sliced into 5 mm sections, and stained with haematoxylin and eosin in accordance with standard procedures for the histological evaluation of colonic damage. Morphological changes in the colonic membrane were observed under a microscope.
MPO activity. Tissue colon samples obtained from the middle colon were weighed and homogenized in 0.5 % (w/v) hexadecyltrimethylammonium bromide in 50 mM potassium phosphate buffer (pH 6.0). The homogenates were then centrifuged for 15 min at 25 000 g at 4 uC. Supernatants were collected for an MPO assay. Fifty microliters of each supernatant sample was added to 200 ml o-dianisidine solution (30 ml 20 mg o-dianisidine dihydrochloride ml 21 and 30 ml 20 mM hydrogen peroxide added into 50 mM potassium phosphate buffer, pH 6.0). After terminating the reaction with sodium azide, the change in absorbance at 460 nm (A 460 ) was read using a microplate reader.
Cytokines and a-MSH measurements. Colon samples were weighed and homogenized in PBS at pH 7.2 containing a protease cocktail at 4 uC and centrifuged at 16 000 g for 10 min. The cytokine levels of TNF-a, IL-6 and IL-10 in the supernatants were determined by ELISA kits in accordance with the manufacturer's instructions (GenStar). Similarly, the level of a-MSH in the colon tissue fluid was measured by an ELISA kit as described above.
Quantification of faecal bifidobacteria. Bifidobacterium quantification in the colon was determined using real-time PCR as described previously (Delroisse et al., 2008) . Collected faecal matter (1 g) was serially diluted 10 times with sterile water, followed by centrifugation for 5 min at 110 g to remove large particles. Cells were collected by centrifugation for 10 min at 7100 g DNA was extracted using a DNA extraction kit (Pico Pure). Afterwards, a real-time PCR assay was performed with primers (forward 59-CGCGTCYGGTGTGAAAG-39, reverse 59-CCCCACATCCAGCATCCA-39), a TaqMan minor groove binder probe (59-AACAGGATTAGATACCC-39) and purified target DNA. The amplified fragment length was 244 bp. The reaction mixture was held at 50 uC for 2 min and 94 uC for 10 min, followed by 40 cycles of amplification at 94 uC for 20 s, and finally at 60 uC for 1 min. Detection was performed using a sequence detection system (ABI Prism 7000; ABI Applied Biosystems). Log c.f.u. g 21 was used to express the number of bifidobacteria.
NO determination. After weighing, the colon samples were homogenized in PBS at pH 7.2 and centrifuged at 25000 g for 15 min at 4 uC. Supernatants were deproteinized by ultrafiltration by using an Ultracel YM-10 membrane (Millipore Amicon). A Nitrite/Nitrate Colorimetric Assay kit was used according to the manufacturer's instructions (Cayman) to detect NO levels.
Statistical analysis. All data in the figures and text are expressed as arithmetic means+SEM. The data are representative of three or more independent experiments. The data were evaluated using GraphPad Prism 5.0. Statistical analysis for significant differences was performed using one-way ANOVA, where appropriate. Pv0.05 was considered statistically significant.
RESULTS

Vector construction
pDG7 is an E. coli-Bifidobacterium shuttle vector, which was selected as the replication origin. To achieve increased expression, the constitutive and highly expressed hup promoter and terminator (Tena et al., 2014) were introduced into the expression system. To improve translation, we added an optimal RBS (Park et al., 2008) downstream of the hup promoter. The amyB signal peptide (Chenoll et al., 2015) was fused in frame with the a-MSH gene to facilitate the secretion of a-MSH from the cells. An oligonucleotide carrying a fusion of RBS, the amyB signal sequence and the a-MSH gene was synthesized using codon optimization for bifidobacteria (Reyes Escogido et al., 2007) . To utilize the signal peptides, we designed two plasmids, pDGMSH1 and pDGMSH2, which consisted of signal peptides with different lengths, with the predicted amino acid sequences shown in 
a-MSH expression
To confirm the transformants of B. longum secreting a-MSH, supernatants from WT strains and transformants of B. longum were analysed by Western blotting. Western blot analysis showed that both pDGMSH1 and pDGMSH2 could produce a-MSH (Fig. 2) . pDGMSH1 was barely expressed and was almost under the level of detection (Fig. 2, lane 2) , which could be ascribed to the failure of the B. longum signal peptidase to cleave the signal peptide. In pDGMSH2, the result showed a prominent band in the Western blot, indicating that rha-MSH was released from the cells. Then, we determined the level of a-MSH secretion from pDGMSH2 over time. The result is shown in Fig. 3 . The concentration of rha-MSH in the supernatants increased along with cell multiplication. The increase was almost terminated when entering the stationary period (the concentration reached 287.72 + 14.90 pg ml 21 in 30 h). This result was possibly caused by the hup promoter, which is closely associated with cell multiplication. When the cells multiplied rapidly, a-MSH expression similarly increased in quantity. By contrast, a-MSH was expressed less when cells were entering the stationary period.
Anti-inflammatory activity of B. longum-a-MSH (B. longum-pDGMSH2)
To determine the biological activity of rha-MSH expressed by B. longum-a-MSH, we tested its anti-inflammation effect with an LPS-induced inflammatory model of HT-29 cells from colon epithelium. Generally, a-MSH executes its anti-inflammatory action via the NF-kB signal pathway (Fabrikant et al., 2013) . We measured the expression levels of NF-kB p65 and IL-8 after treatment with HT-29 cells with adjusted bifidobacterial culture supernatants and LPS. B. longum-a-MSH supernatants (containing 40 pg rha-MSH ml
21
) could significantly inhibit NF-kB p65 expression compared with that of the LPS (Pv0.001) and WT (Pv0.01) group (Fig. 4a) , indicating that rha-MSH was bioactive. From the given data, we observed that WT culture supernatant markedly inhibited NF-kB production (Pv0.01 compared with the LPS group), suggesting that B. longum HB15 can attenuate inflammation (Fig. 4b) . With regard to the IL-8 secretion test, the functional result was found to be similar to NFkB p65 (Fig. 4c) .
Effect of orally administering B. longum-a-MSH to combat DSS-induced colitis
Colitis is characterized by many factors, such as increased MPO activity, unbalanced inflammatory cytokines, elevated NO and colon histological damage. We analysed these factors to evaluate the effects of B. longum-a-MSH on colitis treatment. Rats were orally administered daily with B. longum or not for 7 days after colitis induction. The levels of MPO, TNF-a, IL-6, IL-10 and NO were measured at 1, 3, 5 and 7 days, and histological evaluation was performed.
The MPO enzyme is closely related to IBD. In our experiments, the data reflected that MPO activity of colon tissues on day 7 was significantly (Pv0.01) reduced in the B. longum-a-MSH/DSS group compared with the DSS and WT/DSS groups (10.94 + 0.84 vs 61.88 + 7.07 and Oral Bifidobacterium expressing a-MSH to combat UC 43.73 + 3.63, respectively), suggesting a reduced neutrophil infiltration in colon tissues (Fig. 5 ).
Cytokines serve a critical role in regulating IBD. The data showed that the levels of TNF-a and IL-6 were significantly attenuated (Pv0.05) in the B. (Fig. 6a,  b) . We then measured another cytokine, IL-10, which can exert a strong inflammation inhibitory function by inhibiting the expression of inflammatory cytokines such as IL-1a, IL-1b, IL-6, IL-12, IL-18 and TNF-a (Kuehbacher et al., 2008; Potas et al., 2015) . This cytokine is regarded as a promising therapeutic treatment for IBD (Braat et al., 2003; Park et al., 2015) . On day 7 after oral administration, we observed that IL-10 levels were significantly (Pv0.01) higher in the B. longum-a-MSH/DSS group (380.29+ 25.37 pg ml 21 ). By contrast, the expression of IL-10 declined in the DSS group (87.51 + 6.00 pg ml
21
) and the WT/DSS group (223.77 + 13.93 pg ml 21 ) (Fig. 6c) .
It has been reported that pro-inflammatory cytokines induce the production of inducible nitric oxide synthase (iNOS), which is associated with promoted inflammation, and that abundant iNOS increases the production of freeradical NO . This tissue-fluid NO can contribute to inflammation, thus exacerbating colitis (Krieglstein et al., 2007; Chokshi et al., 2008) . Compared with the DSS and WT/DSS groups, significantly reduced levels of NO were observed in the B. longum-a-MSH/DSS group (8.47 + 0.36 vs 24.01 + 1.52 and 21.60 + 1.01, respectively) (Fig. 7) . To determine the growing states of Bifidobacterium in the intestines, quantification was performed using real-time PCR. As shown in Fig. 8(b) , the number of Bifidobacterium continuously increased in the WT and B. longum-a-MSH groups, whereas in the DSS group, the amount of B. longum decreased. Along with B. longum-a-MSH multiplication, augmentation of rha-MSH concentration in colon tissue fluid was found, suggesting that B. longuma-MSH could successfully express rha-MSH in the colon (Fig. 8a) . To further assess the therapeutic efficacy of B. longum-a-MSH, we observed its protective effects in DSS-induced colitis. The colon histological lesion results are shown in Fig. 9 . Reduced inflammation and less submucosal oedema were observed in the B. longum-a-MSHtreated group.
DISCUSSION
In this study, we successfully constructed an engineered B. longum secreting bioactive a-MSH. We then utilized this engineered bacterium against DSS-induced colitis of rats. The results showed that colitis induced by DSS was significantly alleviated. These results were based on several crucial aspects of IBD: the MPO enzyme is a good marker of inflammatory status and tissue injury, and is expressed by neutrophils, which have a major function in causing colitis, as well as in the pathogenesis of the disease (Gambero et al., 2007; Hensel et al., 2014) . In addition, TNF-a and IL-6 serve a critical function in the modulation of intestinal immunity and inflammation. Considerable research has reported that large amounts of TNF-a and IL-6 are found in the colonic mucosa of UC patients (Cekic et al., 2014) , and that they play a crucial role in the initiation and continuation of mucosal inflammation and immunity (He et al., 2014) . Möller and Villiger (2006) suggested that the blockade of TNF-a and IL-6 could treat inflammatory diseases. In our work, MPO, TNF-a, IL-6 and the pro-inflammatory factor NO were significantly reduced, whereas the anti-inflammatory cytokine IL-10 was significantly increased in the rats fed with B. longum secreting a-MSH, as well as preventing colonic pathological damage and recovering the number of bifidobacteria in the bowel, indicating that this engineered B. longum has a better capacity to control IBD. Our work presents a feasible way to cure IBD that could be of great advantage to those who suffer from this disease.
IBD is a refractory immune-mediated disease. Although much work has been conducted, its exact pathogenesis remains elusive. The conventional treatments for IBD, including corticosteroids, 5-aminosalicylic acid and immunosuppressive drugs, have focused on controlling the inflammation (Triantafyllidi et al., 2015) . However, these pharmaceuticals do not meet some needs of the patients because they have serious adverse events. Therefore, effective new agents should be developed. Substantial research has facilitated progress in IBD prevention, using biological agents such as anti-TNF and anti-CD3 antibodies to block one or several inflammatory cytokines, and which have performed well in colitis of rats. Unfortunately, these treatments are inadequate because IBD is characterized not only by immune disorders and various inflammatory factors but also by abnormalities of the intestinal microflora (Bai & Peng, 2010; Kaser et al., 2010; Cohen et al., 2014) . A comprehensive treatment should not only control inflammation but also ensure the balance of intestinal microflora. Hence, we introduced a-MSH and B. longum probiotics into an anti-inflammatory function trying to resist this serious disease.
Bifidobacterium, a probiotic, modulates gut microbiota balance through the mucosal barrier effect, inhibits the growth of pathogenic bacteria and prevents gastrointestinal diseases. Some studies have indicated that bifidobacteria are well established in controlling IBD, reducing the symptoms of the disease and leading to auxiliary actions in therapy (Kim et al., 2007; Philippe et al., 2011; Meyer et al., 2015) . The results of the current study also support these reports. In addition, decreased counts of Bifidobacterium have been observed in the colon of patients with UC (Macfarlane et al., 2004) , which suggests that these bacteria might have a protective role against UC. The current study agrees with this observation. After B. longum administration, the counts of Bifidobacterium in the colon of rats in our experiment were restored (Fig. 8b) . However, the use of probiotics alone is inadequate and requires further evaluation.
a-MSH is a potent anti-inflammatory peptide that can regulate a broad range of inflammatory cytokines and mediators. This physiological characteristic makes a-MSH a potentially valuable drug for the treatment of inflammation diseases, including IBD. However, the application of this peptide is limited because of its extremely short duration in vivo. Hence, a-MSH is an unsuitable drug. On the contrary, given that a-MSH is a typical peptide, oral delivery of this peptide results in an extremely low bioavailability because of its abundant and unfavourable degradation in the stomach and lack of stability in the luminal environment (Scheuch & Siekmeier, 2007; Singh et al., 2008; Fan et al., 2014) . Taking these two problems into consideration, a particular strategy must be adopted. In the current study, B. longum was chosen as a carrier and we constructed a B. longum expressing a-MSH and used it for UC treatment. Hypothetically, the administration of B. longum expressing a-MSH could continually colonize the enteric canal and express a-MSH, thereby presenting one way to compensate for the short biological half-life of a-MSH. The results presented in our experiment showed that the engineered B. longum survived in the gut and increased rha-MSH expression (Fig. 8) . As expected, rha-MSH fully functioned to increase anti-inflammation to improve UC conditions by significantly inhibiting inflammatory factors such as MPO, TNF-a, IL-6 and NO, and enhancing the anti-inflammatory cytokine IL-10 expression. Given that B. longum survives in the gut, a-MSH should be immediately produced in the location of IBD. This method may be a more reasonable therapy for the disease.
In summary, in this work, we treated DSS-induced colitis by administering B. longum expressing a-MSH. We aimed to solve the problem of the short half-life of a-MSH peptide. In this strategy, we delivered a-MSH peptide via oral administration to circumvent conventional injection, which is uncomfortable for patients. The therapeutic effects could be adjusted based on changes in the condition of the illness, even eliminating the condition by administering suitable antibiotics. In conclusion, our work represents an alternative option to improve experimental IBD by B. longum expressing a-MSH.
